Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01081132 · ClinicalTrials.gov registry record · Phase 3
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 314
- Enrollment target
NCT01081132 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 314 participants.
The verdict
NCT01081132, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 314 participants
- Enrollment target
Study Summary
To assess the efficacy of optimized Extended-release Guanfacine Hydrochloride compared with placebo in the treatment of adolescents aged 13-17 years with a diagnosis of ADHD as measured by the ADHD-RS-IV
Interventions
- OTHER Placebo
- DRUG Extended-release Guanfacine Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2011-09-19 |
| Est. Completion | 2013-05-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01081132
The ClinicalTrials.gov registry entry for NCT01081132 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01081132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01081132 about?
NCT01081132 is a clinical study titled "Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl". To assess the efficacy of optimized Extended-release Guanfacine Hydrochloride compared with placebo in the treatment of adolescents aged 13-17 years with a diagnosis of ADHD as measured by the ADHD-RS-IV
What is the current status of trial NCT01081132?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 314 participants. The study started on 2011-09-19. Estimated completion is 2013-05-16.
What interventions are being tested in trial NCT01081132?
The interventions under investigation include: Placebo (OTHER), Extended-release Guanfacine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01081132?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.